Review Article| Volume 31, ISSUE 3, P547-558, July 2022

Management of Synovial Sarcoma and Myxoid Liposarcoma

  • Nadia Hindi
    Corresponding author. Department of Oncology, Fundación Jimenez Diaz University Hospital, Av Reyes Católicos, 2, Madrid 28040, Spain.
    Department of Oncology, Fundación Jimenez Diaz University Hospital and Hospital General de Villalba, Madrid, Spain

    Health Research Institute Fundación Jimenez Diaz, Universidad Autonoma de Madrid (IIS-FJD, UAM), Madrid, Spain
    Search for articles by this author
  • Rick L. Haas
    Department of Radiotherapy at the Netherlands Cancer Institute, Amsterdam, the Netherlands

    Department of Radiotherapy at the Leiden University Medical Center, Leiden, the Netherlands
    Search for articles by this author


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.


      Subscribe to Surgical Oncology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. Soft tissue and bone tumors, WHO classification of tumours, 5th edition. vol. 3: Lyon, France: IARC; 2020.

        • Clark J.
        • Rocques P.J.
        • Crew A.J.
        • et al.
        Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma.
        Nat Genet. 1994; 7: 502-508
        • Aman P.
        • Ron D.
        • Mandahl N.
        • et al.
        Rearrangement of the transcription factor gene CHOP in myxoid liposarcomas with t(12;16)(q13;p11).
        Genes Chromosomes Cancer. 1992; 5: 278-285
        • Panagopoulos I.
        • Hoglund M.
        • Mertens F.
        • et al.
        Fusion of the EWS and CHOP genes in myxoid liposarcoma.
        Oncogene. 1996; 12: 489-494
        • Vlenterie M.
        • Ho V.K.
        • Kaal S.E.
        • et al.
        Age as an independent prognostic factor for survival of localised synovial sarcoma patients.
        Br J Cancer. 2015; 113: 1602-1606
        • Stacchiotti S.
        • Van Tine B.A.
        Synovial Sarcoma: Current Concepts and Future Perspectives.
        J Clin Oncol. 2018; 36: 180-187
        • Desar I.M.E.
        • Fleuren E.D.G.
        • van der Graaf W.T.A.
        Systemic Treatment for Adults with Synovial Sarcoma.
        Curr Treat Options Oncol. 2018; 19: 13
        • Lansu J.
        • Bovee J.
        • Braam P.
        • et al.
        Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma: A Nonrandomized Controlled Trial.
        JAMA Oncol. 2021; 7: e205865
        • Betgen A.
        • Haas R.L.
        • Sonke J.J.
        Volume changes in soft tissue sarcomas during preoperative radiotherapy of extremities evaluated using cone-beam CT.
        J Radiat Oncol. 2013; 2: 55-62
        • Chung P.W.
        • Deheshi B.M.
        • Ferguson P.C.
        • et al.
        Radiosensitivity translates into excellent local control in extremity myxoid liposarcoma: a comparison with other soft tissue sarcomas.
        Cancer. 2009; 115: 3254-3261
        • Engstrom K.
        • Bergh P.
        • Cederlund C.G.
        • et al.
        Irradiation of myxoid/round cell liposarcoma induces volume reduction and lipoma-like morphology.
        Acta Oncol. 2007; 46: 838-845
        • Pitson G.
        • Robinson P.
        • Wilke D.
        • et al.
        Radiation response: an additional unique signature of myxoid liposarcoma.
        Int J Radiat Oncol Biol Phys. 2004; 60: 522-526
        • Lansu J.
        • Van Houdt W.J.
        • Schaapveld M.
        • et al.
        Time Trends and Prognostic Factors for Overall Survival in Myxoid Liposarcomas: A Population-Based Study.
        Sarcoma. 2020; 2020: 2437850
        • Moreau L.C.
        • Turcotte R.
        • Ferguson P.
        • et al.
        Myxoid∖round cell liposarcoma (MRCLS) revisited: an analysis of 418 primarily managed cases.
        Ann Surg Oncol. 2012; 19: 1081-1088
        • O'Sullivan B.
        • Davis A.M.
        • Turcotte R.
        • et al.
        Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial.
        Lancet. 2002; 359: 2235-2241
        • Van Meekeren M.
        • Fiocco M.
        • Ho V.K.Y.
        • et al.
        Patterns of Perioperative Treatment and Survival of Localized, Resected, Intermediate- or High-Grade Soft Tissue Sarcoma: A 2000-2017 Netherlands Cancer Registry Database Analysis.
        Sarcoma. 2021; 2021: 9976122
        • de Vreeze R.S.
        • de Jong D.
        • Haas R.L.
        • et al.
        Effectiveness of radiotherapy in myxoid sarcomas is associated with a dense vascular pattern.
        Int J Radiat Oncol Biol Phys. 2008; 72: 1480-1487
        • Kosela-Paterczyk H.
        • Szumera-Cieckiewicz A.
        • Szacht M.
        • et al.
        Efficacy of neoadjuvant hypofractionated radiotherapy in patients with locally advanced myxoid liposarcoma.
        Eur J Surg Oncol. 2016; 42: 891-898
        • Gronchi A.
        • Hindi N.
        • Cruz J.
        • et al.
        Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups.
        EClinicalMedicine. 2019; 9: 35-43
        • Martin-Broto J.
        • Hindi N.
        • Lopez-Pousa A.
        • et al.
        Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With Metastatic Soft-Tissue Sarcomas: A Nonrandomized Phase 1/2 Clinical Trial.
        JAMA Oncol. 2020; 6: 535-541
        • Haas R.L.
        • Floot B.G.J.
        • Scholten A.N.
        • et al.
        Cellular Radiosensitivity of Soft Tissue Sarcoma.
        Radiat Res. 2021; 196: 23-30
        • Gingrich A.A.
        • Marrufo A.S.
        • Liu Y.
        • et al.
        Radiotherapy is Associated With Improved Survival in Patients With Synovial Sarcoma Undergoing Surgery: A National Cancer Database Analysis.
        J Surg Res. 2020; 255: 378-387
        • Naing K.W.
        • Monjazeb A.M.
        • Li C.S.
        • et al.
        Perioperative radiotherapy is associated with improved survival among patients with synovial sarcoma: A SEER analysis.
        J Surg Oncol. 2015; 111: 158-164
        • Song S.
        • Park J.
        • Kim H.J.
        • et al.
        Effects of Adjuvant Radiotherapy in Patients With Synovial Sarcoma.
        Am J Clin Oncol. 2017; 40: 306-311
        • Guadagnolo B.A.
        • Zagars G.K.
        • Ballo M.T.
        • et al.
        Long-term outcomes for synovial sarcoma treated with conservation surgery and radiotherapy.
        Int J Radiat Oncol Biol Phys. 2007; 69: 1173-1180
        • van Praag V.M.
        • Rueten-Budde A.J.
        • Jeys L.M.
        • et al.
        A prediction model for treatment decisions in high-grade extremity soft-tissue sarcomas: Personalised sarcoma care (PERSARC).
        Eur J Cancer. 2017; 83: 313-323
        • Callegaro D.
        • Miceli R.
        • Bonvalot S.
        • et al.
        Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis.
        Lancet Oncol. 2016; 17: 671-680
        • Callegaro D.
        • Miceli R.
        • Bonvalot S.
        • et al.
        Development and external validation of a dynamic prognostic nomogram for primary extremity soft tissue sarcoma survivors.
        EClinicalMedicine. 2019; 17: 100215
        • Woll P.J.
        • Reichardt P.
        • Le Cesne A.
        • et al.
        Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial.
        Lancet Oncol. 2012; 13: 1045-1054
        • Frustaci S.
        • Gherlinzoni F.
        • De Paoli A.
        • et al.
        Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial.
        J Clin Oncol. 2001; 19: 1238-1247
        • Gronchi A.
        • Ferrari S.
        • Quagliuolo V.
        • et al.
        Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
        Lancet Oncol. 2017; 18: 812-822
        • Gronchi A.
        • Frustaci S.
        • Mercuri M.
        • et al.
        Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group.
        J Clin Oncol. 2012; 30: 850-856
        • Gronchi A.
        • Palmerini E.
        • Quagliuolo V.
        • et al.
        Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups.
        J Clin Oncol. 2020; 38: 2178-2186
        • Nielsen O.S.
        • Judson I.
        • van Hoesel Q.
        • et al.
        Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group.
        Eur J Cancer. 2000; 36: 61-67
        • Issels R.D.
        • Lindner L.H.
        • Verweij J.
        • et al.
        Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial.
        JAMA Oncol. 2018; 4: 483-492
        • Blay J.Y.
        • van Glabbeke M.
        • Verweij J.
        • et al.
        Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy.
        Eur J Cancer. 2003; 39: 64-69
        • Italiano A.
        • Mathoulin-Pelissier S.
        • Cesne A.L.
        • et al.
        Trends in survival for patients with metastatic soft-tissue sarcoma.
        Cancer. 2011; 117: 1049-1054
        • Tap W.D.
        • Wagner A.J.
        • Schoffski P.
        • et al.
        Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial.
        JAMA. 2020; 323: 1266-1276
        • Gronchi A.
        • Miah A.B.
        • Dei Tos A.P.
        • et al.
        Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up.
        Ann Oncol. 2021; 32: 1348-1365
        • Visgauss J.D.
        • Wilson D.A.
        • Perrin D.L.
        • et al.
        Staging and Surveillance of Myxoid Liposarcoma: Follow-up Assessment and the Metastatic Pattern of 169 Patients Suggests Inadequacy of Current Practice Standards.
        Ann Surg Oncol. 2021; 28: 7903-7911
        • Navarria P.
        • Ascolese A.M.
        • Cozzi L.
        • et al.
        Stereotactic body radiation therapy for lung metastases from soft tissue sarcoma.
        Eur J Cancer. 2015; 51: 668-674
        • Judson I.
        • Verweij J.
        • Gelderblom H.
        • et al.
        Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
        Lancet Oncol. 2014; 15: 415-423
        • Katz D.
        • Boonsirikamchai P.
        • Choi H.
        • et al.
        Efficacy of first-line doxorubicin and ifosfamide in myxoid liposarcoma.
        Clin Sarcoma Res. 2012; 2: 2
        • Spurrell E.L.
        • Fisher C.
        • Thomas J.M.
        • et al.
        Prognostic factors in advanced synovial sarcoma: an analysis of 104 patients treated at the Royal Marsden Hospital.
        Ann Oncol. 2005; 16: 437-444
        • Sleijfer S.
        • Ouali M.
        • van Glabbeke M.
        • et al.
        Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
        Eur J Cancer. 2010; 46: 72-83
        • Venkatramani R.
        • Xue W.
        • Randall R.L.
        • et al.
        Synovial Sarcoma in Children, Adolescents, and Young Adults: A Report From the Children's Oncology Group ARST0332 Study.
        J Clin Oncol. 2021; 39: 3927-3937
        • Rosen G.
        • Forscher C.
        • Lowenbraun S.
        • et al.
        Synovial sarcoma. Uniform response of metastases to high dose ifosfamide.
        Cancer. 1994; 73: 2506-2511
        • Martin-Liberal J.
        • Alam S.
        • Constantinidou A.
        • et al.
        Clinical activity and tolerability of a 14-day infusional Ifosfamide schedule in soft-tissue sarcoma.
        Sarcoma. 2013; 2013: 868973
        • Buesa J.M.
        • Lopez-Pousa A.
        • Martin J.
        • et al.
        Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS).
        Ann Oncol. 1998; 9: 871-876
        • Noujaim J.
        • Constantinidou A.
        • Messiou C.
        • et al.
        Successful Ifosfamide Rechallenge in Soft-Tissue Sarcoma.
        Am J Clin Oncol. 2018; 41: 147-151
        • Lee S.H.
        • Chang M.H.
        • Baek K.K.
        • et al.
        High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients.
        Oncology. 2011; 80: 257-261
        • Le Cesne A.
        • Antoine E.
        • Spielmann M.
        • et al.
        High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas.
        J Clin Oncol. 1995; 13: 1600-1608
        • Colia V.
        • Fumagalli E.
        • Provenzano S.
        • et al.
        High-Dose Ifosfamide Chemotherapy in a Series of Patients Affected by Myxoid Liposarcoma.
        Sarcoma. 2017; 2017: 3739159
        • Di Giandomenico S.
        • Frapolli R.
        • Bello E.
        • et al.
        Mode of action of trabectedin in myxoid liposarcomas.
        Oncogene. 2014; 33: 5201-5210
        • Grosso F.
        • Jones R.L.
        • Demetri G.D.
        • et al.
        Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study.
        Lancet Oncol. 2007; 8: 595-602
        • Sanfilippo R.
        • Dileo P.
        • Blay J.Y.
        • et al.
        Trabectedin in advanced synovial sarcomas: a multicenter retrospective study from four European institutions and the Italian Rare Cancer Network.
        Anticancer Drugs. 2015; 26: 678-681
        • van der Graaf W.T.
        • Blay J.Y.
        • Chawla S.P.
        • et al.
        Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.
        Lancet. 2012; 379: 1879-1886
        • Sleijfer S.
        • Ray-Coquard I.
        • Papai Z.
        • et al.
        Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).
        J Clin Oncol. 2009; 27: 3126-3132
        • Mir O.
        • Brodowicz T.
        • Italiano A.
        • et al.
        Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial.
        Lancet Oncol. 2016; 17: 1732-1742
        • Chi Y.
        • Fang Z.
        • Hong X.
        • et al.
        Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma.
        Clin Cancer Res. 2018; 24: 5233-5238
        • Wang Y.
        • Lu M.
        • Zhou Y.
        • et al.
        The Efficacy and Safety of Apatinib in Advanced Synovial Sarcoma: A Case Series of Twenty-One Patients in One Single Institution.
        Cancer Manag Res. 2020; 12: 5255-5264
        • Schoffski P.
        • Chawla S.
        • Maki R.G.
        • et al.
        Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.
        Lancet. 2016; 387: 1629-1637
        • Demetri G.D.
        • Schoffski P.
        • Grignani G.
        • et al.
        Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine.
        J Clin Oncol. 2017; 35: 3433-3439
        • Seddon B.
        • Strauss S.J.
        • Whelan J.
        • et al.
        Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
        Lancet Oncol. 2017; 18: 1397-1410
        • Maki R.G.
        • Wathen J.K.
        • Patel S.R.
        • et al.
        Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].
        J Clin Oncol. 2007; 25: 2755-2763
        • Garcia-Del-Muro X.
        • Lopez-Pousa A.
        • Maurel J.
        • et al.
        Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study.
        J Clin Oncol. 2011; 29: 2528-2533
        • Hale R.
        • Sandakly S.
        • Shipley J.
        • et al.
        Epigenetic Targets in Synovial Sarcoma: A Mini-Review.
        Front Oncol. 2019; 9: 1078
        • Kawano S.
        • Grassian A.R.
        • Tsuda M.
        • et al.
        Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma.
        PLoS One. 2016; 11e0158888
        • Schoffski P.A.M.
        • Stacchiotti S.
        • Davis L.E.
        • et al.
        Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with synovial sarcoma.
        J Clin Oncol. 2017; 35: 1057-11057
      2. NCT04965753. 2022. Available at: Accessed February 17, 2022.

        • Endo M.
        • de Graaff M.A.
        • Ingram D.R.
        • et al.
        NY-ESO-1 (CTAG1B) expression in mesenchymal tumors.
        Mod Pathol. 2015; 28: 587-595
        • Jungbluth A.A.
        • Antonescu C.R.
        • Busam K.J.
        • et al.
        Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7.
        Int J Cancer. 2001; 94: 252-256
        • Hemminger J.A.
        • Ewart Toland A.
        • Scharschmidt T.J.
        • et al.
        The cancer-testis antigen NY-ESO-1 is highly expressed in myxoid and round cell subset of liposarcomas.
        Mod Pathol. 2013; 26: 282-288
        • Pollack S.M.
        • Jungbluth A.A.
        • Hoch B.L.
        • et al.
        NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma.
        Cancer. 2012; 118: 4564-4570
        • Kakimoto T.
        • Matsumine A.
        • Kageyama S.
        • et al.
        Immunohistochemical expression and clinicopathological assessment of the cancer testis antigens NY-ESO-1 and MAGE-A4 in high-grade soft-tissue sarcoma.
        Oncol Lett. 2019; 17: 3937-3943
        • Iura K.
        • Maekawa A.
        • Kohashi K.
        • et al.
        Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1.
        Hum Pathol. 2017; 61: 130-139
        • D'Angelo S.P.
        • Melchiori L.
        • Merchant M.S.
        • et al.
        Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 (c259)T Cells in Synovial Sarcoma.
        Cancer Discov. 2018; 8: 944-957
        • Mitchell G.
        • Pollack S.M.
        • Wagner M.J.
        Targeting cancer testis antigens in synovial sarcoma.
        J Immunother Cancer. 2021; 9: e002072
        • Martin-Broto J.
        • Moura D.S.
        • Van Tine B.A.
        Facts and Hopes in Immunotherapy of Soft-Tissue Sarcomas.
        Clin Cancer Res. 2020; 26: 5801-5808